Patents Examined by Rodney P Swartz
  • Patent number: 10323070
    Abstract: The present invention relates to DNA sequences encoding Vmp-like polypeptides of pathogenic Borrelia, the use of the DNA sequences in recombinant vectors to express polypeptides, the encoded amino acid sequences, application of the DNA and amino acid sequences to the production of polypeptides as antigens for immunoprophylaxis, immunotherapy, and immunodiagnosis. Also disclosed are the use of the nucleic acid sequences as probes or primers for the detection of organisms causing Lyme disease, relapsing fever, or related disorders, and kits designed to facilitate methods of using the described polypeptides, DNA segments and antibodies.
    Type: Grant
    Filed: May 31, 2017
    Date of Patent: June 18, 2019
    Assignee: BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventor: Steven J. Norris
  • Patent number: 10324090
    Abstract: This disclosure provides a method for detecting infection of an animal by Mycobacterium bovis. The method generally includes obtaining a biological sample from a host animal at risk of being infected by Mycobacterium bovis and analyzing the sample for the presence or absence of at least one M. bovis polypeptide. In some embodiments, the method can further include analyzing the sample for the presence or absence of at least one M. bovis lipid. In some embodiments, the method can further include detecting at least one host polypeptide whose expression is greater in a host infected with M. bovis compared to expression in a host known to be uninfected with M bovis.
    Type: Grant
    Filed: November 21, 2014
    Date of Patent: June 18, 2019
    Assignee: REGENTS OF THE UNIVERSITY OF MINNESOTA
    Inventors: Srinand Sreevatsan, Elise Lamont
  • Patent number: 10314867
    Abstract: The present invention relates to a composition comprising Bifidobacterium bacteria for use for reducing intestinal gas production in an individual.
    Type: Grant
    Filed: April 23, 2015
    Date of Patent: June 11, 2019
    Assignee: COMPAGNIE GERVAIS DANONE
    Inventors: Boris Le Neve, Émilie Rocher, Denis Guyonnet
  • Patent number: 10295538
    Abstract: The present invention relates to Mycobacterium tuberculosis (M tuberculosis) proteins and immunologically active fragments (peptides or mimotope peptides) thereof. In particular, the invention relates to a group of M. tuberculosis proteins and peptides thereof that are both highly antigenic and characteristic of clinical strains of M. tuberculosis. Accordingly, the further relates to the use of these M. tuberculosis proteins or peptides in diagnosing, treating or preventing M. tuberculosis complex infection.
    Type: Grant
    Filed: August 14, 2015
    Date of Patent: May 21, 2019
    Assignee: Oxford Immunotec Limited
    Inventors: Massimo Amicosante, Ian Durrant, Scott Tasker
  • Patent number: 10287342
    Abstract: The present invention relates to novel polypeptide for binding to a complement protein C5a. More particularly, the present invention relates to polypeptide which can be bound to a complement protein C5a and inhibit the activation of same, polynucleotide which codes for the polypeptide, a recombinant vector which comprises the polynucleotide, a recombinant microorganism to which the recombinant vector has been introduced, a method for producing the polypeptide by means of the recombinant microorganism, and a pharmaceutical composition, for treating immune diseases or sepsis, containing the polypeptide. A polypeptide, according to the present invention, can be bound to a complement protein C5a, with higher affinity compared to being bound to a complement protein C5a receptor which is present in nature, and inhibits the activation of same, thus being widely utilized for development of formulation for preventing or treating diseases related to a complement protein C5a.
    Type: Grant
    Filed: August 3, 2015
    Date of Patent: May 14, 2019
    Assignee: KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: Hak-Sung Kim, Da Eun Hwang, Jung-Min Choi, Joong-Jae Lee, Woosung Heu
  • Patent number: 10288610
    Abstract: Provided are assays, kits and compositions for testing subjects, particularly asymptomatic subjects, to ascertain whether or not they are carriers of Salmonella enterica serotype Typhi. Methods for detecting the presence of Salmonella enterica serotype Typhi indicating molecules by a variety of methods such as immunoassays and mass spectrometry also are provided.
    Type: Grant
    Filed: November 12, 2013
    Date of Patent: May 14, 2019
    Assignees: THE GENERAL HOSPITAL CORPORATION, INTERNATIONAL CENTRE FOR DIARRHOEAL DISEASE RESEARCH, BANGLADESH (ICDDR,B), THE CHANGELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD
    Inventors: Richelle Charles, Edward T. Ryan, Firdausi Qadri, Stephen Baker
  • Patent number: 10287641
    Abstract: The invention relates to new isolated Lactobacillus strains chosen from Lactobacillus mellifer Bin4N.sup.T (LMG P-28344) and Lactobacillus apinorum Fhon13N.sup.T (LMG P-28345), which have been isolated from honeybees or their processed food. The bacterial strains have unique properties such as production of benzene, free fatty acids and 2-heptanone, rendering them useful in many areas such as in food and beverage products, feed products and medical products.
    Type: Grant
    Filed: August 13, 2015
    Date of Patent: May 14, 2019
    Assignee: CONCELLAE AB
    Inventors: Tobias Olofsson, Alejandra Vasquez
  • Patent number: 10286053
    Abstract: The present invention is directed to a polypeptide which comprises: (i) an Rv2386c protein sequence; (ii) a variant of an Rv2386c protein sequence; of (iii) an immunogenic fragment of an Rv2386c protein sequence. In other aspects the invention is directed to associated polynucleotides, fusion proteins and methods for the treatment or prevention of tuberculosis.
    Type: Grant
    Filed: September 15, 2016
    Date of Patent: May 14, 2019
    Assignee: GLAXOSMITHKLINE BIOLOGICALS S.A.
    Inventors: Pascal Mettens, James Brown, Dennis Murphy
  • Patent number: 10273265
    Abstract: Provided herein is a novel epitope that can be used as a tag in methods for rapid and effective characterization, purification, and subcellular localization of polypeptides of interest, which comprise the tag. The tag is specifically recognized by an epitope specific antibody, which can be used to detect, capture, quantify, and/or purify polypeptides of interest that are tagged with the epitope. Also provided is novel epitope specific antibody.
    Type: Grant
    Filed: November 16, 2016
    Date of Patent: April 30, 2019
    Assignees: NMI NATURWISSENSCHAFTLICHES UND MEDIZINISCHES INSTITUT AN DER UNIVERSITÄT TÜBINGEN, CHROMOTEK GMBH
    Inventors: Ulrich Rothbauer, Oliver Poetz, Tina Romer, Andrea Buchfellner, Larisa Yurlova, Kourosh Zolghadr, Jaqueline Bogner, Benjamin Ruf, Christian Linke-Winnebeck, Michael Metterlein
  • Patent number: 10273469
    Abstract: The invention relates to probiotic bacteria selected from lactic acid bacteria, such as Lactobacillus and Bifidobacteria, having metals and/or metal nanoparticles and to foodstuff and pharmaceutical composition having these bacteria. The invention also provides methods for obtaining these bacteria and uses of these bacteria for the treatment and prevention of mineral deficiency pathologies, as a contrast agent for the imaging of the digestive tract and for the treatment of cancer.
    Type: Grant
    Filed: June 24, 2014
    Date of Patent: April 30, 2019
    Assignee: BIOSEARCH, S.A.
    Inventors: Jose Manuel Dominguez Vera, Natividad Galvez Rodriguez, Miguel Angel Martin Marcos, Fernando Carmona Rodriguez-Acosta, Deyanira Rondon Rodriguez, Monica Olivares Martin
  • Patent number: 10265395
    Abstract: The present disclosure provides for an adjuvant composition that is suited for injectable as well as transdermal administration. The adjuvant composition generally comprises a lipophile, a polymer of acrylic or methacrylic acid, saline, cholesterol, a saponin, and sodium hydroxide. A vaccine composition is also provided for that generally includes the vaccine composition of the present disclosure and a DNA component. A method for vaccinating animals and humans utilizing the adjuvant composition of the present disclosure is also provided.
    Type: Grant
    Filed: March 23, 2017
    Date of Patent: April 23, 2019
    Inventors: Timothy J Miller, Mary Ann Pfannenstiel
  • Patent number: 10239920
    Abstract: The present invention discloses methods and materials for delivering a cargo compound into a cancer cell. Delivery of the cargo compound is accomplished by the use of protein transduction domains derived from cupredoxins. The invention further discloses methods for treating cancer and diagnosing cancer.
    Type: Grant
    Filed: October 19, 2015
    Date of Patent: March 26, 2019
    Assignee: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
    Inventors: Ananda Chakrabarty, Tapas Das Gupta, Tohru Yamada, Arsenio Fialho
  • Patent number: 10238738
    Abstract: Novel methods and uses for modulating immune responses are provided. The methods and uses involve the use of a TIFA activator such heptose-1,7-5 bisphosphate or an analog or derivative thereof. The methods may be used to activate, inhibit or otherwise modify an immune response so as to either prevent or treat infectious or inflammatory diseases or cancer. Also provided are methods to identify compounds capable of modulating immune responses.
    Type: Grant
    Filed: October 9, 2015
    Date of Patent: March 26, 2019
    Assignee: The Governing Council of the University of Toronto
    Inventors: Scott Gray-Owen, Ryan Gaudet, Rebecca Malott
  • Patent number: 10232027
    Abstract: A live attenuated Edwardsiella ictaluri bacterium lacking a viable gene encoding a functional evpB protein and a method of using the same to protect fish against infection from virulent Edwardsiella ictaluri. The methods and compositions for protecting fish against infection from virulent Edwardsiella ictaluri comprising administering to a fish a therapeutically effective amount of an attenuated Edwardsiella ictaluri bacterium lacking a viable gene encoding a functional EvpB protein. The bacterium may include an insertion and/or deletion mutation in the evpB gene. The fish include catfish, preferably catfish fingerling or a catfish fry. The composition may be delivered via immersion delivery, an injection delivery, an oral delivery, or combinations thereof.
    Type: Grant
    Filed: September 6, 2016
    Date of Patent: March 19, 2019
    Assignee: MISSISSIPPI STATE UNIVERSITY
    Inventors: Attila Karsi, Mark L. Lawrence, Hossam Abdelhamed
  • Patent number: 10232036
    Abstract: The present invention provides a vaccine formulation, a preparation method therefor and a use thereof. The vaccine formulation comprises a vaccine carrier and an antigen component, wherein the vaccine carrier is obtained by hydrothermal transformation of microorganisms. The vaccine formulation of the present invention is obtained by compounding the vaccine carrier obtained by hydrothermal transformation of microorganisms with the antigen component.
    Type: Grant
    Filed: November 18, 2015
    Date of Patent: March 19, 2019
    Assignee: INSTITUTE OF PROCESS ENGINEERING, CHINESE ACADEMY OF SCIENCES
    Inventors: Guanghui Ma, Wei Wei, Dezhi Ni, Hua Yue, Weiqing Zhou, Piping Lv
  • Patent number: 10232026
    Abstract: Disclosed is a vaccine which has a high therapeutic effect on mycoplasma infection and is highly safe. For the purpose of developing effective therapeutic methods for mycoplasma infection, mycoplasma-mimic particles which are effective as a vaccine for mycoplasma infection are provided, and also provided are bacterium-mimic particles including common bacteria. Bacterium-mimic particles such as mycoplasma-mimic particles can be provided by producing liposome particles in which a lipid antigen specific to a pathogenic bacterium such as mycoplasma is contained as a liposome-constituting lipid component. The administration of the mycoplasma-mimic particles enables the induction of a potent immunological activity in living bodies. The mycoplasma-mimic particles can be used as an excellent vaccine for the prevention or treatment of mycoplasma infection.
    Type: Grant
    Filed: December 13, 2016
    Date of Patent: March 19, 2019
    Assignees: NATIONAL INSTITUTE OF INFECTIOUS DISEASES, M BIO TECHNOLOGY INC.
    Inventors: Kazuhiro Matsuda, Koji Ichiyama, Sachie Matsuda, Yuko Sasaki, Yoshichika Arakawa, Ryo Harasawa, Yoshihiro Nishida, Norio Katayama, Yasuo Endo, Nobuo Nomura
  • Patent number: 10232028
    Abstract: The present invention discloses isolates and fractions from a phyto-percolate and methods for affecting various cytokines by administering an effective amount of one or more of said isolates or fractions to an animal. In various exemplary embodiments, the isolates are useful for the treatment of bovine, canine and swine infection or inflammation, including bovine mastitis, by regulation of TNF-a, lactoferrin, IFN-?, IL-I ?, serum amyloid-A (SAA), IL-6 and/or ?-defensin associated with infection or an immune response generally.
    Type: Grant
    Filed: June 13, 2014
    Date of Patent: March 19, 2019
    Assignee: ZIVO BIOSCIENCE, INC.
    Inventor: Andrew Dahl
  • Patent number: 10232037
    Abstract: The invention relates to the application of peptides that can self-assemble to form supramolecular nanofibrils and hydrogels, hydrogel compositions containing the self-assembled supramolecular nanofibrils, and methods of uses and making the hydrogel compositions.
    Type: Grant
    Filed: May 29, 2014
    Date of Patent: March 19, 2019
    Assignees: Brandeis University, Children's Medical Center Corporation
    Inventors: Fan Zhao, Jingyu Li, Hongbo R. Luo, Bing Xu
  • Patent number: 10226060
    Abstract: The present invention relates to a Myoviridae bacteriophage Lac-GAP-1 that is isolated from the nature and can kill specifically Lactococcus garvieae cells, which has a genome represented by the nucleotide sequence of SEQ ID NO: 1 (Accession NO: KCTC 12686BP), and a method for preventing and treating the infections of Lactococcus garvieae using the composition comprising said bacteriophage as an active ingredient.
    Type: Grant
    Filed: January 5, 2016
    Date of Patent: March 12, 2019
    Assignee: INTRON BIOTECHNOLOGY, INC.
    Inventors: Seong Jun Yoon, Sang Hyeon Kang, Soo Youn Jun, An Sung Kwon, Soon Hye Hwang
  • Patent number: 10226494
    Abstract: The present invention relates to an antioxidant composition containing an extracellular polysaccharide produced using Ceriporia lacerata, or a mycelium culture of Ceriporia lacerata comprising the same, or a dry powder or an extract thereof as an active ingredient. The composition can be used as an antioxidant for preventing or treating various diseases such as brain diseases such as stroke, Parkinson's disease, etc., heart diseases, ischemia, arteriosclerosis, skin damage, inflammation, rheumatism, autoimmune diseases, etc. including cancers as well as aging, or as a health functional food, a cosmetic material or a feed composition having an antioxidant effect.
    Type: Grant
    Filed: November 27, 2015
    Date of Patent: March 12, 2019
    Assignee: FUGENBIO CO., LTD.
    Inventor: Yoon Soo Kim